Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $107.54 in the prior trading day, Zimmer Biomet Holdings Inc (NYSE: ZBH) closed at $106.79, down -0.70%. In other words, the price has decreased by -$0.70 from its previous closing price. On the day, 0.85 million shares were traded. ZBH stock price reached its highest trading level at $107.84 during the session, while it also had its lowest trading level at $106.25.
Ratios:
Our goal is to gain a better understanding of ZBH by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 37.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.07. For the most recent quarter (mrq), Quick Ratio is recorded 0.96 and its Current Ratio is at 1.87. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.54.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 18 ’25 when Winkler Lori sold 1,500 shares for $102.49 per share. The transaction valued at 153,735 led to the insider holds 8,333 shares of the business.
Bezjak Mark bought 7,500 shares of ZBH for $766,708 on Aug 13 ’25. On Jun 13 ’25, another insider, Yi Sang, who serves as the Group President, Asia Pacific of the company, sold 800 shares for $92.51 each. As a result, the insider received 74,011 and left with 19,624 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBH now has a Market Capitalization of 21154672640 and an Enterprise Value of 28328570880. As of this moment, Zimmer’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.00, and their Forward P/E ratio for the next fiscal year is 12.46. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.06. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.70 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 3.616 whereas that against EBITDA is 10.944.
Stock Price History:
The Beta on a monthly basis for ZBH is 0.69, which has changed by -0.06871891 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, ZBH has reached a high of $116.71, while it has fallen to a 52-week low of $89.22. The 50-Day Moving Average of the stock is 10.74%, while the 200-Day Moving Average is calculated to be 4.50%.
Shares Statistics:
The stock has traded on average 1.87M shares per day over the past 3-months and 1338330 shares per day over the last 10 days, according to various share statistics. A total of 197.90M shares are outstanding, with a floating share count of 197.82M. Insiders hold about 0.14% of the company’s shares, while institutions hold 98.92% stake in the company. Shares short for ZBH as of 1755216000 were 6961467 with a Short Ratio of 3.72, compared to 1752537600 on 7336928. Therefore, it implies a Short% of Shares Outstanding of 6961467 and a Short% of Float of 4.03.
Dividends & Splits
In the trailing 12 months, ZBH’s forward annual dividend rate was 0.96, compared to 0.96 this year. Against a Trailing Annual Dividend Yield of 0.00892691The stock’s 5-year Average Dividend Yield is 0.78. The current Payout Ratio is 21.66% for ZBH, which recently paid a dividend on 2025-06-26 with an ex-dividend date of 2025-09-30. Stock splits for the company last occurred on 2022-03-01 when the company split stock in a 103:100 ratio.
Earnings Estimates
A detailed examination of Zimmer Biomet Holdings Inc (ZBH) is currently in progress, with 25.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $2.39, with high estimates of $2.49 and low estimates of $2.15.
Analysts are recommending an EPS of between $8.21 and $7.93 for the fiscal current year, implying an average EPS of $8.14. EPS for the following year is $8.56, with 27.0 analysts recommending between $9.01 and $8.31.
Revenue Estimates
23 analysts predict $2.01B in revenue for the current quarter. It ranges from a high estimate of $2.03B to a low estimate of $1.98B. As of the current estimate, Zimmer Biomet Holdings Inc’s year-ago sales were $1.82BFor the next quarter, 23 analysts are estimating revenue of $2.23B. There is a high estimate of $2.25B for the next quarter, whereas the lowest estimate is $2.21B.
A total of 26 analysts have provided revenue estimates for ZBH’s current fiscal year. The highest revenue estimate was $8.25B, while the lowest revenue estimate was $8.11B, resulting in an average revenue estimate of $8.22B. In the same quarter a year ago, actual revenue was $7.68BBased on 25 analysts’ estimates, the company’s revenue will be $8.69B in the next fiscal year. The high estimate is $8.83B and the low estimate is $8.29B.
